Eduardo Franco Chris Meijer
  Eduardo Franco
(McGill University,
Chris Meijer
(Vrije Universiteit,

Dear Friends of EUROGIN,

Fifteen years have passed since the first European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Paris in 1994. In that year we saw the beginning of the concerted actions that eventually brought the new challenges that we face today in deploying the new promising strategies for preventing cervical cancer, namely human papillomavirus (HPV) vaccination and improved screening tests based on molecular technologies. Over the years, this vibrant organization has served as main clinical and scientific forum for the open and frank discussions that facilitated research and development on prophylactic HPV vaccines and on new screening methods for cervical cancer control. EUROGIN has been extremely successful in catalyzing the intellectual interactions among clinicians, basic scientists, epidemiologists, microbiologists, public health practitioners, health economists, disease advocates, and industry-based researchers. From the initial phase of triennial conferences in Paris to the nearly annual congresses of recent years that included events in Nice and in Monte Carlo, the organization has unequivocally become the premier forum for all professionals engaged in the fight against cervical cancer and the nefarious consequences it has on the lives of so many underprivileged populations throughout the world. EUROGIN has also been true to its mission of educating clinicians and the public health community in using the best diagnostic and prevention tools in the control of genital infections and its associated neoplastic diseases.

Although it is based in France and was originally aimed as an education and clinical discussion forum for European countries, EUROGIN quickly acquired an international scope and considerably expanded the roster of specialties and subspecialties that cater to the control of cervical cancer and other HPV-associated diseases. EUROGIN’s remarkable success has inspired the establishment of sister organizations in Latin America and Asia to focus on specific problems shared by clinicians, academics, and policymakers at a regional level.

For 2010, EUROGIN once again invites you to join in the discussions under the aegis of “CERVICAL CANCER PREVENTION: 20 YEARS OF PROGRESS AND A PATH TO THE FUTURE”, a theme that articulates the historical developments of the past with a vision for the next phase of our collective battle against the above diseases. Glamorous Monte Carlo provides again the backdrop for our congress, the first since the Nobel Prize in Physiology and Medicine has been awarded to Professor Harald Zur Hausen for his monumental research achievements that characterized HPV infection as the cause of cervical cancer and other malignancies.

Please mark February 17-20, 2010 in your calendar and come to Monte Carlo to be part of this most multi-disciplinary of the conferences in the field of cervical cancer control. Add your voice to the exciting debate on how to best employ the new technologies of prophylactic HPV vaccination and cervical cancer screening. Learn about the challenges in deploying these technologies and be inspired by the candid discussions among the world’s foremost experts. We are confident that you will be energized by the interactions and by the high-level exchanges on circumventing the obstacles for cost-effective cervical cancer control. Whether you are a clinician who wonders how your HPV-vaccinated patients should be screened or a public health practitioner tasked to assist your country in using the most solid evidence to implement cervical cancer prevention strategies EUROGIN 2010 will not disappoint you; you will be exposed to the most up-to-the minute knowledge from all related areas.

We are honored with the opportunity of welcoming you to the Grimaldi Convention Centre in Monaco in 2010. Once again, led by the dynamic leadership of Dr. Joseph Monsonego, the EUROGIN congress will provide you with an exciting education and scientific programme that includes all relevant topics for cervical cancer control professionals. A stellar and truly international Scientific Programme Committee has assisted Dr. Monsonego and his EUROGIN secretariat in making the 2010 congress a memorable event. On behalf of the organizers we are grateful for the constant support that the biotechnology and pharmaceutical industrial partners have provided to the congress.

Please visit the conference’s website frequently to be updated on the constantly evolving agenda. Prominent speakers have been confirmed for exciting plenary and symposium sessions, training courses, and satellite events. Be sure to submit your most recent research findings to the offered communications sessions. Although most sessions are held in English, EUROGIN has been the home for the French-language PROGIN, a parallel event that congregates professionals from francophone countries. Even if your mother language is not English or French, EUROGIN is for you; chances are that you will meet with your compatriots in the corridors of the Grimaldi Forum on February 17-20, 2010. Finally, be prepared to have a busy time trying to profit from so many learning opportunities packed in a 4-day congress. At the end of an exhaustive day attending sessions you will have the comfort of socializing with friends and colleagues from around the world in the charming Mediterranean surroundings of Monaco and the French Riviera.

Wishing you a wonderful experience at EUROGIN 2010,

Eduardo Franco (McGill University, Montreal)
Chris Meijer (Vrije Universiteit, Amsterdam)

Congress Honorary Presidents